⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 20, 2019PLoS MedicineOpen Access

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

View Full Paper

Ask AI

Bookmark

Share

Authors

TCThomas CallenderUniversity of Cambridge MEMark EmbertonUniversity College London SMStephen MorrisGuy's and St Thomas' NHS Foundation Trust

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Callender et al. (2019) studied this question.

synapsesocial.com/papers/69df0c73b8d7e9456661432a https://doi.org/10.1371/journal.pmed.1002998

View Full Paper

Ask AI

Bookmark

Share